Femara (letrozole) provides both anticancer responses and disease stabilization in a significant number of patients with recurrent, estrogen receptor positive ovarian cancer. The results of the study were published in Clinical Cancer Research.
Femara blocks levels of estrogen in the body, ultimately reducing or preventing growth of estrogen positive cancer cells. Femara has been demonstrated to be effective for estrogen positive breast cancer, but has not yet had a clear influence in women with ovarian cancer.
Forty two patients were part of a clinical trial to evaluate the effectiveness of Femara. At three months, 42 percent of patients achieved disease stabilization and 9 percent achieved a regression of their disease. At over six months, 26 percent of patients still did not have progression of their disease measured by CA125 levels in the blood.
The researchers concluded that Femara may provide an effective and well tolerated treatment alternative for patients with recurrent, estrogen positive ovarian cancer.
1. I have been during the last 5 years on Tamoxifn + Femara. Now my Doctor informed me that's it
no more Femara!!!
How am I gona protect myself???
Is Femara dangerous/ineefective after 24 months of usage??
Posted at 1:23AM on Aug 5th 2007 by Rafi Farhat